Form 4: ADMA Biologics Director Lawrence P. Guiheen Reports Stock and Option Transactions

Director Lawrence P. Guiheen reports acquisition of restricted stock units and stock options in ADMA Biologics, along with adjustments to existing holdings.

Summary

• On February 26, 2024, Lawrence P. Guiheen, a director of ADMA Biologics, reported transactions involving ADMA Biologics' common stock and stock options.
• Guiheen acquired 24,040 restricted stock units (RSUs) that will vest in two equal installments over the next year.
• He also acquired 37,541 stock options with an exercise price of $5.40, vesting monthly over one year and expiring in 2034.
• Following these transactions, Guiheen directly owns 153,941 shares of common stock, including the newly granted RSUs, and indirectly owns 1,000 shares through the Guiheen Trust.
• He also directly owns 37,541 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports transactions by a company director, which is a routine occurrence. There is no explicit positive or negative information about the company's performance or outlook.

Positives

• The acquisition of RSUs and stock options by a director could be interpreted as a sign of confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the director's investment activities in the company.

Key Dates